Skip to main content
Top
Published in: Clinical Rheumatology 5/2015

01-05-2015 | Original Article

ANCA-associated vasculitis in Hispanic Americans: an unrecognized severity

Authors: Antoine G. Sreih, Ranadeep Mandhadi, Fadi Aldaghlawi, Asad Khan, Vajiha Irshad, Katherine Finn, Joel A. Block

Published in: Clinical Rheumatology | Issue 5/2015

Login to get access

Abstract

This study aims to compare the severity and outcomes of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) between Hispanics and Caucasians living in the same geographical area. All patients diagnosed with AAV at two academic institutions in Chicago from January 2006 to December 2012 were retrospectively and prospectively identified. Disease activity was measured with the Birmingham Vasculitis Activity Score (BVAS), and disease damage was measured with the Vasculitis Damage Index (VDI). Student’s t test and chi-square tests were employed; p ≤ 0.05 was considered significant. Seventy patients with AAV were identified; 15 patients were excluded. Fifty-five patients were included in the study: 23 Hispanics and 32 Caucasians, 35 patients with granulomatosis with polyangiitis (Wegener’s), 12 with microscopic polyangiitis, 7 with eosinophilic granulomatosis with polyangiitis, and 1 with renal-limited vasculitis. Compared to Caucasians, Hispanics had a higher BVAS at presentation (16.3 ± 7.6 versus 10.7 ± 7.5, p = 0.006), a higher VDI at presentation (2.90 ± 1.50 versus 2.06 ± 1.30, p = 0.030), and a cumulative VDI (3.90 ± 1.70 versus 2.50 ± 1.90, p = 0.010). Renal involvement was more common among Hispanics (85 % of Hispanics versus 48 % of Caucasians, p = 0.01). Seventy percent of Hispanics had acute renal failure (mean creatinine = 3.37 ± 4.4 mg/dl) of whom seven (50 %) required dialysis, versus 25 % of Caucasians (mean creatinine = 1.78 ± 1.57 mg/dl, p = 0.03) and only two requiring dialysis. Compared to Caucasians, Hispanics with AAV present with more severe disease and higher damage indices. Larger studies are required to confirm these findings and delineate the respective roles of environment and genetics in the pathogenesis of the disease.
Literature
1.
go back to reference Lane SE, Watts RA et al (2005) Primary systemic vasculitis: clinical features and mortality. QJM 98(2):97–111CrossRefPubMed Lane SE, Watts RA et al (2005) Primary systemic vasculitis: clinical features and mortality. QJM 98(2):97–111CrossRefPubMed
2.
go back to reference Cartin-Ceba R, Peikert T, Specks U (2012) Pathogenesis of ANCA-associated vasculitis. Curr Rheumatol Rep 14(6):481–493CrossRefPubMed Cartin-Ceba R, Peikert T, Specks U (2012) Pathogenesis of ANCA-associated vasculitis. Curr Rheumatol Rep 14(6):481–493CrossRefPubMed
3.
go back to reference Martorana D, Maritati F et al (2012) PTPN22 R620W polymorphism in the ANCA-associated vasculitides. Rheumatology 51(5):805–812CrossRefPubMed Martorana D, Maritati F et al (2012) PTPN22 R620W polymorphism in the ANCA-associated vasculitides. Rheumatology 51(5):805–812CrossRefPubMed
4.
go back to reference Tse WY, Abadeh S et al (2000) Neutrophil FcgammaRIIIb allelic polymorphism in anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis. Clin Exp Immunol 119(3):574–577CrossRefPubMedCentralPubMed Tse WY, Abadeh S et al (2000) Neutrophil FcgammaRIIIb allelic polymorphism in anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis. Clin Exp Immunol 119(3):574–577CrossRefPubMedCentralPubMed
5.
go back to reference Esnault VL, Testa A et al (1993) Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int 43(6):1329–1332CrossRefPubMed Esnault VL, Testa A et al (1993) Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int 43(6):1329–1332CrossRefPubMed
6.
go back to reference Watts RA, Gonzalez-Gay MA et al (2001) Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe. Ann Rheum Dis 60(2):170–172CrossRefPubMedCentralPubMed Watts RA, Gonzalez-Gay MA et al (2001) Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe. Ann Rheum Dis 60(2):170–172CrossRefPubMedCentralPubMed
7.
go back to reference WEGT Research Group (2005) Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 352(4):351–361CrossRef WEGT Research Group (2005) Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 352(4):351–361CrossRef
8.
go back to reference Burgos PI, McGwin G Jr et al (2011) US patients of Hispanic and African ancestry develop lupus nephritis early in the disease course: data from LUMINA, a multiethnic US cohort (LUMINA LXXIV). Ann Rheum Dis 70(2):393–394CrossRefPubMedCentralPubMed Burgos PI, McGwin G Jr et al (2011) US patients of Hispanic and African ancestry develop lupus nephritis early in the disease course: data from LUMINA, a multiethnic US cohort (LUMINA LXXIV). Ann Rheum Dis 70(2):393–394CrossRefPubMedCentralPubMed
9.
go back to reference Alarcon GS, Friedman AW et al (1999) Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture. Lupus 8(3):197–209CrossRefPubMed Alarcon GS, Friedman AW et al (1999) Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture. Lupus 8(3):197–209CrossRefPubMed
10.
go back to reference Fries JF, Hunder GG et al (1990) The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summ Arthritis Rheum 33(8):1135–1136CrossRef Fries JF, Hunder GG et al (1990) The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summ Arthritis Rheum 33(8):1135–1136CrossRef
11.
go back to reference Jennette JC, Falk RJ et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37(2):187–192CrossRefPubMed Jennette JC, Falk RJ et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37(2):187–192CrossRefPubMed
12.
go back to reference Luqmani RA, Bacon PA et al (1994) Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 87(11):671–678PubMed Luqmani RA, Bacon PA et al (1994) Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 87(11):671–678PubMed
13.
go back to reference Mukhtyar C, Lee R et al (2009) Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 68(12):1827–1832CrossRefPubMed Mukhtyar C, Lee R et al (2009) Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 68(12):1827–1832CrossRefPubMed
14.
go back to reference Exley AR, Bacon PA et al (1997) Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 40(2):371–380CrossRefPubMed Exley AR, Bacon PA et al (1997) Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 40(2):371–380CrossRefPubMed
15.
go back to reference Reinhold-Keller E, Herlyn K et al (2005) Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum 53(1):93–99CrossRefPubMed Reinhold-Keller E, Herlyn K et al (2005) Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum 53(1):93–99CrossRefPubMed
16.
go back to reference Fujimoto S, Watts RA et al (2011) Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology 50(10):1916–1920CrossRefPubMed Fujimoto S, Watts RA et al (2011) Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology 50(10):1916–1920CrossRefPubMed
17.
go back to reference Mahr A, Guillevin L et al (2004) Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 51(1):92–99CrossRefPubMed Mahr A, Guillevin L et al (2004) Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 51(1):92–99CrossRefPubMed
18.
go back to reference O’Donnell JL, Stevanovic VR et al (2007) Wegener's granulomatosis in New Zealand: evidence for a latitude-dependent incidence gradient. Int Med J 37(4):242–246CrossRef O’Donnell JL, Stevanovic VR et al (2007) Wegener's granulomatosis in New Zealand: evidence for a latitude-dependent incidence gradient. Int Med J 37(4):242–246CrossRef
19.
go back to reference Flores-Suarez LF, Villa AR (2007) Spectrum of Wegener granulomatosis in a Mexican population. Ann N Y Acad Sci 1107:400–409CrossRefPubMed Flores-Suarez LF, Villa AR (2007) Spectrum of Wegener granulomatosis in a Mexican population. Ann N Y Acad Sci 1107:400–409CrossRefPubMed
20.
go back to reference Cisternas M, Soto L et al (2005) Clinical features of Wegener granulomatosis and microscopic polyangiitis in Chilean patients. Rev Med Chil 133(3):273–278CrossRefPubMed Cisternas M, Soto L et al (2005) Clinical features of Wegener granulomatosis and microscopic polyangiitis in Chilean patients. Rev Med Chil 133(3):273–278CrossRefPubMed
21.
go back to reference Mahr A, Guillevin L et al (2004) Prevalences of polyarteritis nodosa, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Arthritis Rheum 51(1):92–99CrossRefPubMed Mahr A, Guillevin L et al (2004) Prevalences of polyarteritis nodosa, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Arthritis Rheum 51(1):92–99CrossRefPubMed
22.
go back to reference Reveille JD, Moulds JM et al (1998) Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum 41(7):1161–1172CrossRefPubMed Reveille JD, Moulds JM et al (1998) Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum 41(7):1161–1172CrossRefPubMed
23.
go back to reference Contreras G, Lenz O et al (2006) Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int 69(10):1846–1851CrossRefPubMed Contreras G, Lenz O et al (2006) Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int 69(10):1846–1851CrossRefPubMed
24.
go back to reference Mahr A, Girard T et al (2001) Analysis of factors predictive of survival based on 49 patients with systemic Wegener’s granulomatosis and prospective follow-up. Rheumatology 40(5):492–498CrossRefPubMed Mahr A, Girard T et al (2001) Analysis of factors predictive of survival based on 49 patients with systemic Wegener’s granulomatosis and prospective follow-up. Rheumatology 40(5):492–498CrossRefPubMed
25.
go back to reference Takala JH, Kautiainen H et al (2010) Survival of patients with Wegener’s granulomatosis diagnosed in Finland in 1981–2000. Scand J Rheumatol 39(1):71–76CrossRefPubMed Takala JH, Kautiainen H et al (2010) Survival of patients with Wegener’s granulomatosis diagnosed in Finland in 1981–2000. Scand J Rheumatol 39(1):71–76CrossRefPubMed
26.
go back to reference Sanchez AA, Acevedo EM et al (2006) Epidemiology of the primary systemic vasculitides in a Latin-American population. Arthritis Rheum 54(9):S757 Sanchez AA, Acevedo EM et al (2006) Epidemiology of the primary systemic vasculitides in a Latin-American population. Arthritis Rheum 54(9):S757
Metadata
Title
ANCA-associated vasculitis in Hispanic Americans: an unrecognized severity
Authors
Antoine G. Sreih
Ranadeep Mandhadi
Fadi Aldaghlawi
Asad Khan
Vajiha Irshad
Katherine Finn
Joel A. Block
Publication date
01-05-2015
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 5/2015
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-014-2617-z

Other articles of this Issue 5/2015

Clinical Rheumatology 5/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.